Good morning, everyone, and welcome to another working week. We hope the weekend respite was somehow relaxing and invigorating, despite the challenges circulating the globe. On a personal note, we received sad news that our colleague, the accomplished and indefatigable science writer Sharon Begley, passed away. We will drink a cup or more of stimulation this morning in her memory. Meanwhile, here are some tidbits to get the day started. After all, the world keeps spinning. Hope all goes well, and stay safe — wear a mask. …

U.S. health officials are pleading for more use of Covid-19 antibody therapies from Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN) that have been plagued by logistical issues, lack of efficacy data, and insufficient reimbursement, Bloomberg News reports. The drugs, which were touted by President Trump and once feared to be subject to rationing because of demand, have instead been underused. As little as 5% of the supply available was being used in some areas in December, and utilization is now about 20% to 25% of regimens distributed to states.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]